Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 127 results for "Tecfidera Treated Patients"

New Data at CMSC Assess Real-World Impact of Rebif® (interfer...

- Data compare Rebif vs. Tecfidera® and Aubagio® in the first year of treatment - Assessments include likelihood of relapse, medical costs and outpatient management resources needs 09:00 ET from EMD Serono ROCKLAND, Mass., June 2, 2016 ... PR Newswire, 1 month ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 3 months ago
Motley Fool

An Investing Overview of the Multiple Sclerosis Market

Image source: . The market for multiple sclerosis drugs is worth $19 billion annually and treatment advances could lead to significant shifts in market share. Can market share Goliath Biogen ( NASDAQ:BIIB ) sidestep competitive risk? Or, will ...
 Motley Fool4 days ago Onset of Parkinson's Disease May Be Slowed by Metabolite in MS Drug, Mouse Study Shows  Parkinson'sNewsToday.com1 month ago Biogen's MS Drug Fails to Meet Goals in Study  Bioscience Technology Online1 month ago Biogen's MS drug misses main goal in mid-stage study  Yahoo! India1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 7, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency2 weeks ago

Key Pharma News Issue - Companies Target Ever Rarer Diseases with No Real Therapeutic Options and Patient Groups Become More Empowered - Research and Markets

Research and Markets has announced the addition of the "Key Pharma News Issue 50" report to their offering. Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand As companies target ever rarer diseases with no real ...
 4 Traders1 month ago Dynamics Within Industry-Academia Partnerships Changing - Research and Markets  Benzinga.com1 month ago

Biogen's top commercial exec leaves amid Tecfidera sales trouble

When a top biopharma executive abruptly shoves off, what comes next? Questions. Make that departing exec a sales-and-marketing chief, and couple that departure with slowing sales of a key product, and the questions multiply. Tony Kingsley That's ...
 FiercePharma1 week ago

Alkermes Plc (ALKS) Richard Pops on Q2 2016 Results - Earnings Call Transcript

Alkermes plc (NASDAQ: ALKS ) Q2 2016 Earnings Conference Call July 28, 2016 08:30 AM ET Executives Sandra Coombs - Director of Investor Relations Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Analysts Jon Eckard - ...
 Seeking Alpha1 day ago Biogen Needs To Fill Pipeline Or Rethink Strategy  Seeking Alpha1 week ago Biogen (BIIB) George A. Scangos on Q2 2016 Results - Earnings Call Transcript  Seeking Alpha1 week ago Long Biogen: Sohn Investment Idea Contest Entry  Seeking Alpha1 month ago

Medicare Safeguard Overwhelmed by Pricey Drugs

WASHINGTON A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense, government numbers show. The cost of Medicare's catastrophic prescription coverage ...
 Caribbean Business Online5 days ago

Evgen Pharma and the power of plants for potential drug breakthrough

Evgen is a small company hoping to make a major splash with a plant-derived drug How many of us as children sat for the final five minutes of a meal pushing that last stem of broccoli around the plate to the parental refrain: eat your greens, theyre ...
 Proactive days ago

Biogen Beats, Raises: Bye, Bye Bear Move, Hello Bull?

Introduction The large biotech company Biogen (NASDAQ: BIIB ) continues to let little grass grow under its feet; it keeps changing as fast as it can; the question is whether that's fast enough after the company's and the stock's troubles the past ...
 Seeking Alpha1 week ago Biogen Keys To Value In 2017 And Beyond  Seeking Alpha1 month ago

Biogen CEO Scangos to Step Down -- WSJ

The plans for change at the top come as the company topped second-quarter expectations, provided an upbeat earnings outlook and unveiled a $5 billion share buyback. Biogen shares gained 7.6% on Thursday, to $282.45, paring the stock's year-to-date ...
 Nasdaq1 week ago Biogen : Announces CEO Search, Lifts Guidance--2nd Update  4 Traders1 week ago Biogen CEO to Step Down  Investors Hub1 week ago BIOGEN : CEO to Step Down  4 Traders1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less